Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis

被引:103
作者
Mikkola, KM
Patel, SR
Parker, JA
Grodstein, F
Goldhaber, SZ
机构
[1] BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115
[2] LUND UNIV,SCH MED,LUND,SWEDEN
[3] HOSP UNIV PENN,PHILADELPHIA,PA 19104
[4] HARVARD UNIV,SCH MED,BOSTON,MA
[5] BETH ISRAEL HOSP,BOSTON,MA 02215
关键词
D O I
10.1016/S0002-8703(97)70108-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We reviewed our database of 312 patients with pulmonary embolism who received thrombolysis in Five clinical trials. At baseline, none bad a history of stroke, internal bleeding within 6 months, surgery within 10 days, or occult blood in stool. Sixty-six major bleeding episodes occurred within 72 hours of administering thrombolysis in 61 (20%) patients: bleeding at the catheterization site (34 cases), gross hematuria (9), intracranial hemorrhage (5), and 18 other bleeding episodes that led to at least a 10% hematocrit decrease. Patients with a major bleeding complication were on average older than patients with no hemorrhagic complication (mean age 62.9 +/- 1.9 years vs 56.2 +/- 1.1 years; p = 0.005). In an adjusted analysis, there was a fourfold increased risk of bleeding among patients older than 70 years compared with patients younger than 50 years (relative risk [RR] 3.9; 95% confidence interval [Cl] 1.7 to 8.9). By using age as a continuous variable, we found a 4% (RR 1.04; 95% CI 1.02 to 1.06) increase in risk of bleeding For each incremental year of age. In addition, patients with higher body moss index had an increased risk of bleeding. Patients who had undergone catheterization had a five times greater risk of bleeding (RR 5.2; 95% CI 1.5 to 17.8). In summary, increasing age, larger body mass index, and catheterization predisposed to bleeding complications after pulmonary embolism thrombolysis.
引用
收藏
页码:69 / 72
页数:4
相关论文
共 14 条
[1]   THE USE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR FOR ACUTE MYOCARDIAL-INFARCTION IN THE ELDERLY - RESULTS FROM THROMBOLYSIS IN MYOCARDIAL-INFARCTION PHASE-I, OPEN LABEL STUDIES AND THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION PHASE-II PILOT-STUDY [J].
CHAITMAN, BR ;
THOMPSON, B ;
WITTRY, MD ;
STUMP, D ;
HAMILTON, WP ;
HILLIS, LD ;
DWYER, JG ;
SOLOMON, RE ;
KNATTERUD, GL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 14 (05) :1159-1165
[2]   Clinical presentation and results of thrombolytic therapy in older patients with massive pulmonary embolism: A comparison with non-elderly patients [J].
Gisselbrecht, M ;
Diehl, JL ;
Meyer, G ;
Collignon, MA ;
Sors, H .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1996, 44 (02) :189-193
[3]   RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR VERSUS A NOVEL DOSING REGIMEN OF UROKINASE IN ACUTE PULMONARY-EMBOLISM - A RANDOMIZED CONTROLLED MULTICENTER TRIAL [J].
GOLDHABER, SZ ;
KESSLER, CM ;
HEIT, JA ;
ELLIOTT, CG ;
FRIEDENBERG, WR ;
HEISELMAN, DE ;
WILSON, DB ;
PARKER, JA ;
BENNETT, D ;
FELDSTEIN, ML ;
SELWYN, AP ;
KIM, DS ;
SHARMA, GVRK ;
NAGEL, JS ;
MEYEROVITZ, MF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (01) :24-30
[4]   ALTEPLASE VERSUS HEPARIN IN ACUTE PULMONARY-EMBOLISM - RANDOMIZED TRIAL ASSESSING RIGHT-VENTRICULAR FUNCTION AND PULMONARY PERFUSION [J].
GOLDHABER, SZ ;
HAIRE, WD ;
FELDSTEIN, ML ;
MILLER, M ;
TOLTZIS, R ;
SMITH, JL ;
DASILVA, AMT ;
COME, PC ;
LEE, RT ;
PARKER, JA ;
MOGTADER, A ;
MCDONOUGH, TJ ;
BRAUNWALD, E .
LANCET, 1993, 341 (8844) :507-511
[5]  
GOLDHABER SZ, 1986, LANCET, V2, P886
[6]   PERSPECTIVES ON TREATMENT OF ACUTE PULMONARY-EMBOLISM WITH TISSUE PLASMINOGEN-ACTIVATOR [J].
GOLDHABER, SZ ;
MARKIS, JE ;
KESSLER, CM ;
MEYEROVITZ, MF ;
KIM, D ;
VAUCHAN, DE ;
SELWYN, AP ;
LOSCALZO, J ;
DAWLEY, DL ;
SHARMA, GVRK ;
SASAHARA, A ;
GROSSBARD, EB ;
BRAUNWALD, E .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1987, 13 (02) :171-177
[7]  
GOLDHABER SZ, 1988, LANCET, V2, P293
[8]   THROMBOLYTIC THERAPY OF ACUTE PULMONARY-EMBOLISM - CURRENT STATUS AND FUTURE POTENTIAL [J].
GOLDHABER, SZ ;
MEYEROVITZ, MF ;
MARKIS, JE ;
KIM, DS ;
KESSLER, CM ;
SHARMA, GVRK ;
VAUGHAN, DE ;
SELWYN, AP ;
DAWLEY, DL ;
LOSCALZO, J ;
SASAHARA, AA ;
GROSSBARD, EB ;
BRAUNWALD, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (05) :B96-B104
[9]   REDUCED DOSE BOLUS ALTEPLASE VS CONVENTIONAL ALTEPLASE INFUSION FOR PULMONARY-EMBOLISM THROMBOLYSIS - AN INTERNATIONAL MULTICENTER RANDOMIZED TRIAL [J].
GOLDHABER, SZ ;
AGNELLI, G ;
LEVINE, MN .
CHEST, 1994, 106 (03) :718-724
[10]   A RANDOMIZED TRIAL OF A SINGLE BOLUS DOSAGE REGIMEN OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH ACUTE PULMONARY-EMBOLISM [J].
LEVINE, M ;
HIRSH, J ;
WEITZ, J ;
CRUICKSHANK, M ;
NEEMEH, J ;
TURPIE, AG ;
GENT, M .
CHEST, 1990, 98 (06) :1473-1479